A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors

Jordi Rodon, Hussein A. Tawbi, Anne L. Thomas, Ronald G. Stoller, Christian P. Turtschi, Jose Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine L. Rose, Dereck D. Amakye, Reinhard Dummer, Alain C. Mita

Research output: Contribution to journalArticlepeer-review

155 Scopus citations

Fingerprint Dive into the research topics of 'A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences